Aurinia Pharmaceuticals (AUPH) Posts Wider Q2 Loss

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of ($0.26), $0.12 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $29 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• Crown Crafts (CRWS) Reports Q4 EPS of $0.03
• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’